Australia's most trusted
source of pharma news
Friday, 14 February 2025
Posted 30 January 2025 AM
Despite being snubbed by the TGA and consequently pulling a co-dependent reimbursement submission for Leqembi, Eisai has confirmed that work is well underway to make the Alzheimer's disease (AD) treatment available in Australia.
While Eisai and Biogen are co-commercialising and co-promoting Leqembi, also known as lecanemab, Eisai serves as the head of Leqembi development and regulatory submissions globally. The Japanese firm also has the final decision-making authority.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.